Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The COST-Vendor Director leads the end-to-end outsourcing of one or more indications and supports governance of external service providers for current and future clinical trials for multiple Development functions, with a strong emphasis on Clinical Vendors (e.g., CRO’s, imaging, cardiac, IRT, data management, Pharmacovigilance, etc.) Responsibilities include partnering with the clinical operations and other functional teams for clinical vendor identification, creation of requests for information/proposal (RFIs/RFPs), service provider selection, contract negotiations, budget and contract lifecycle management, and facilitating service provider governance, including Key Performance Indicators (KPIs) and performance metrics. This position would report to the Senior Director, COST Vendor Team.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director
Number of Employees
251-500 employees